NCT03656835View on ClinicalTrials.gov

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

November 19, 2025

Study Completion Date

November 19, 2025

Conditions
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma
Interventions
PROCEDURE

Molecular Nanotechnology

Undergo ILN biochip testing

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT03656835 - Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter